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Abstract 
Plakin crosslinking proteins are important structural elements that are expressed in 
many animal tissues, especially those which require resistance to mechanical stress. The three 
plakin proteins most prevalent in skeletal muscle are plectin, dystonin and microtubule-actin 
crosslinking factor (MACF). Skeletal muscle atrophy linked to inactivity is a complex 
phenomenon involving widespread alteration of muscle physiology, often characterized by 
expression of normally repressed embryonic genes in adult muscle. We investigate the 
response of the plakins: plectin, dystonin and MACF to denervation-induced atrophy in mice. 
We found that MACF, which is expressed more abundantly during embryonic development, is 
upregulated following denervation both at the mRNA and protein level as assessed using qPCR 
and western blotting. Plectin and dystonin were both downregulated at the mRNA level but 
remained constant or even upregulated at the protein level, indicating their potential 
importance in the baseline preservation of the skeletal muscle structure following denervation-
induced atrophy. 
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Chapter 1 
1. Introduction 
Voluntary movement is one of the key elements which differentiate animals (Kingdom 
Animalia) from other organisms such as plants (Kingdom Plantae) (Slack et al. 1993). In 
mammals, including humans, skeletal muscle, through its close interaction with the somatic 
nervous system, converts energy into movement (MacIntosh et al. 2006).  Complex 
physiological processes underlie proper muscle function and it is vital to understand these 
mechanisms, as they shed light on skeletal muscle adaptability.  The structure and function of 
skeletal muscle are altered in various movement-impairing pathologies, which can affect the 
ability of people to carry out their activities of daily life (Mitchell et al. 2012; Kharraz et al. 2014; 
Chatzifrangkeskou et al. 2015). At the other end of the spectrum, skeletal muscle tissue is 
known to change its phenotype in response to exercise and this is especially important in the 
case of athletic/sport performance, where a good result is often intimately linked with skeletal 
muscle function (Timmons 2011; Phillips 2014). Understanding how muscles adapt at both ends 
of the spectrum of health and illness has the potential to inform training programs and 
therapies to optimize muscle function and movement. 
1.1. Healthy skeletal muscle tissue 
Skeletal muscle is an excitable tissue capable of generating force through contraction.  
Skeletal muscle tissue, as well as cardiac muscle, display a unique structure and subcellular 
organization characterized by striations; as such it is also known as ‘striated muscle.’  Skeletal 
muscle cells are multinucleated, elongated structures which contain contractile elements 
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known as sarcomeres. Sarcomeres are complex arrangements of multiple proteins. Actin and 
myosin, the main contractile proteins, are arranged with great precision and regularity. Their 
overlap causes the visible striations in muscle (Clark et al. 2002; MacIntosh et al. 2006). Figure 
1-1, adapted from Braun & Gautel, (2011) illustrates the sarcomere. Its components will be 
discussed. 
 
 
Figure 1-1: An illustration of the sarcomere, the fundamental contractile unit of muscle. 
Shown are the Z-disks (whose main component is α-actinin), the interaction of actin filaments 
and titin with the Z-disks as well as the spring-like function of titin. The M-band is also shown. In 
the M-band, proteins including myomesin crosslink myosin filaments near the centre of the 
sarcomere. Above, skeletal muscle (left) and cardiac muscle (right) are shown. They both 
contain sarcomeres, but their morphology is different. Skeletal muscle has peripheral nuclei 
whereas cardiac muscle does not (adapted from Braun & Gautel, 2011). 
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1.1.1. Actin filaments 
Actin is expressed in all mammalian tissues, including muscle (Dominiguez & Holmes 
2011). There are three main actin isoforms in vertebrates: Alpha (α)-actin, Beta (β)-actin and 
Gamma (γ)-actin. These isoforms organize into a protein known as globular (G)-actin. G-actin is 
a globular protein that is folded into two main domains (small and large) which are each divided 
into two subdomains, where subdomains 1 and 2 are part of the small domain and subdomains 
3 and 4 are part of the large subdomain (Dominiguez & Holmes 2011). Globular actin 
polymerizes into a polymer known as Filamentous (F)-actin. F-actin is the protein which forms 
the actin filaments depicted in Figure 1-1. This long strand of actin forms a helix where 
approximately six turns are completed for every 13 globular actin molecules (Dominiguez & 
Holmes 2011).  
1.1.2. Myosin filaments 
Myosin filaments are polymers of myosin. There are many isoforms of myosin divided 
into 15 classes. The focus for this thesis will be Class II Myosins. Class II myosins are known as 
“conventional” myosins; they are found in muscle cells and they form filaments which 
hydrolyze adenosine triphosphate (ATP) to produce movement through interactions with actin 
(Sellers 2000).  Myosin filaments are composed of subunits of two myosin heavy chains (MHC) 
and four myosin light chains (MLC) (Clark et al. 2002). Two of the MLCs have a regulatory 
function, while the second pair of MLCs is structural. The MHCs are arranged in a way as to 
form a separate ‘head’ region, where the binding sites protrude from the myosin filaments and 
interact with actin to initiate muscle contraction (MacIntosh et al. 2006). The remainder of the 
myosin molecules interact towards the center of the filament and polymerize, creating the 
myosin filament itself. Myosin filaments terminate at the M-band (see Figure 1-1) at the center 
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of the sarcomere where they interact with proteins such as myomesin to form a cohesive 
structure of thick myosin filaments. 
1.1.3. Titin 
Titin is a large protein with a molecular weight of roughly 4200kDa in humans (Bang et 
al. 2001). It is the largest known protein and the third most abundant protein in muscle, after 
actin and myosin (Clark et al. 2002). It reaches from the  Z-line to the M-line and spans the 
entire sarcomere (Trinick & Tskhovrebova 2010). It is thought to provide structure and elastic 
properties to the muscle as demonstrated in Figure 1-1 where titin is depicted as a spring-like 
coil.  This giant protein has been shown to slightly change shape under small applied forces 
while under large forces, the polypeptide unravels, returning to its shorter state when force is 
no longer applied (Trinick & Tskhovrebova 2010). When isolated outside of the sarcomere, titin 
does not maintain its rod shape but assumes a coiled appearance (Trinick & Tskhovrebova 
2010), which indicates a certain amount of passive elasticity even when the sarcomere is at 
rest. 
1.1.4. Z-disk proteins 
The Z-disk, also known as the Z-line because when viewed as two dimensional 
longitudinal cross sections of muscle it appears as a line, is the limit of a sarcomere; a 
sarcomere spans from Z-disk to Z-disk. The Z-disk is a complex network of proteins that include 
α-actinin and many other proteins not shown in Figure 1-1.  Alpha-actinin is the most abundant 
protein of the Z-disk and one of its functions is to cross-link actin filaments (Faulkner et al. 
2001).  Alpha-actinin also binds other proteins at the Z-disk, with structural or regulatory 
functions (Faulkner et al. 2001). One example is nebulin, a protein which binds to α-actinin at 
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its C-terminal end and its N-terminal end extends to the tips of actin filaments where it 
regulates actin filament length (Clark et al. 2002). Desmin, the most abundant intermediate 
filament in muscle, also binds to the Z-disk (Capetanaki et al. 2007).  
Intermediate filaments are very important in muscle structure, but they are not part of 
the sarcomere. Their implication in the structural rigidity of muscle is discussed below. Filamin 
is another important protein which binds to α-actinin at the Z-disk and to sarcoglycans at the 
Dystrophin Glycoprotein complex (DGC), an important anchor site near the sarcolemma for 
force transduction in muscle (Clark et al. 2002). Evidently, the Z-disk is an important adhesion 
structure in muscle which crosslinks many important structural and regulatory proteins. 
1.2. Cytoskeletal proteins and the structure of the skeletal muscle cell 
Skeletal muscle cells have distinct morphology compared to other cells. One major 
difference is the positioning of their nuclei, which are peripherally located in mature cells (see 
Figure 1-1). Skeletal muscle mitochondria are also more numerous than in other cells, such as 
epithelial cells (Hoppeler & Fluck 2003). Mitochondria are localized in pairs adjacent to z-disks 
through plectin and desmin binding, but are also located between the sarcolemma and the 
myofibrils (Reipert et al. 1999; Picard et al. 2012); desmin intermediate filaments are important 
elements of the skeletal muscle cytoskeleton.  
The cytoskeleton is an intricate network of large structural proteins which interact in 
order to provide structure to the cell. Cytoskeletal proteins are polymers that are often large 
enough to span the width of the entire cell (Erickson 2007). The three main components of the 
cytoskeleton are microtubules (tubulin subunits), microfilaments (actin subunits) and 
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intermediate filaments (e.g. desmin, especially in muscle). The main components of the 
cytoskeleton are interconnected or crosslinked by large proteins belonging to the plakin family 
(described below), thought to act as scaffolding proteins which solidify the cell architecture 
(Bouameur et al. 2014). 
1.3. Plakins 
Plakins are a class of cytolinker proteins which bind to various elements of the 
cytoskeleton but also to various organelles and cell membrane proteins. Plakins are found in all 
metazoa, but not in eukaryotes such as yeast (Suozzi et al. 2012). They likely evolved to fulfill 
specific structural roles in the cells of higher animals. Drosophila, or fruit flies, contain only one 
plakin gene, known as short stop/kakapo, which codes a small number of different isoforms 
through alternative splicing (Suozzi et al. 2012). In mammals such as mice and humans, there 
are many plakin genes coding a large number of isoforms. These include dystonin, Microtubule-
Actin Crosslinking Factor (MACF), plectin, periplakin, epiplakin, envoplakin and desmoplakin 
(Ferrier et al. 2013). It has been postulated that plakins evolved to fulfill the need for structural 
integrity in highly mobile animals as their tissues have the potential to deform more than in 
insects. These diverse mammalian plakin isoforms may have some form of functional 
redundancy during developmental phases (Ferrier et al. 2013). However, many plakin 
mutations are lethal as demonstrated in desmoplakin knockout mice (Jefferson et al. 2004) and 
in VAB10-mutated C. Elegans (VAB10 is the plakin version of MACF in C. Elegans) (Bosher et al. 
2003). In this sense, plakins are not always functionally redundant. 
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1.4. Mammalian plakin diversity 
1.4.1. Plakins versus spectraplakins 
Plakins evolved from proteins known as spectrins. Some plakin isoforms still contain 
spectrin repeat domains, which are characteristic of spectrins, but also contain plakin repeat 
domains. These proteins are known as spectraplakins. However, some authors have criticized 
this distinction because it was found that plakin repeat domains themselves evolved from 
spectrins and should still be characterized as spectrins (Sonnenberg & Liem 2007). This would 
mean that all proteins containing plakin repeat domains are spectraplakins, rendering the 
distinction useless. However, even if plakin repeat domains show similar sequence similarity to 
spectrin repeats and can be shown to be derived from spectrin repeats, they are still 
functionally distinct. Spectraplakins have roles not shared with plakin family proteins which 
have lost their spectrin repeat domains (Sonnenberg & Liem 2007).  Spectraplakins can span 
larger distances in the cell due to the rod-like spectrin repeats which add length to the protein. 
Of the seven plakin proteins, only MACF and dystonin are considered spectraplakins. 
1.4.2. Dystonin 
The dystonin gene in mammals is a very large gene which codes a variety of proteins 
through alternative splicing (Leung et al. 2001). In fact, diverse plakin protein variants are 
produced via alternative splicing of a limited numbers of genes and not as a result of 
transcription of numerous genes. There are three main isoforms of dystonin: dystonin-a, 
dystonin-b and dystonin-e (which are neural, muscle and epithelial isoforms, respectively). Of 
these isoforms, there are variants of a and b with different N- or C- terminal regions producing 
even more complexity. For example, dystonin-a has isoform a1, a2 and a3, each with 
functionally distinct N-terminal regions. One N-terminal region binds to actin and another has a 
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transmembrane domain. The following figure from Ferrier et al. (2013) illustrates these 
dystonin isoforms: 
 
Figure 1-2: The three dystonin isoforms and the various N-terminal binding domains of 
dystonin-a & -b (adapted from Ferrier et al. 2013) 
 
Figure 1-2 demonstrates that dystonin-e differs considerably from dystonin-a and 
dystonin-b. This epithelial isoform lacks spectrin repeats, making it similar to the non-
spectraplakins described later (see section 1.4.5). 
1.4.3. MACF 
Microtubule-Actin Crosslinking Factor (MACF) is another important structural protein of 
the spectraplakin family with an N-terminal Actin binding domain and a C-terminal Growth 
Arrest Specific 2 (GAS2)-like protein domain which binds to microtubules (Sun et al. 2000).  
MACF contains 23 spectrin repeats which serve to elongate the protein allowing it to span large 
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distances within the cell - crucial for its function. It is the most similar protein to Drosophila 
Short Stop, as is its function (Sanchez-Soriano et al. 2009). It is also similar to dystonin, sharing 
up to 88% sequence similarity at the amino acid level (Karakesisoglou 2000). When the function 
of MACF is compromised, cellular microtubules are disorganized and structurally compromised 
(Karakesisoglou et al. 2000). When short stop (MACF analog) is inhibited through RNA 
interference (RNAi), microtubules networks are less able to resist forces within the cell, such as 
those created by molecular motors during organelle transport, and they show significant lateral 
movement (Applewhite et al. 2010). Knockdown of MACF in mouse neurons resulted in 
microtubule networks being diffuse compared to the tighter microtubule networks in normal 
neurons, and a similar effect was observed in a short stop knockdown model (Sanchez-Soriano 
et al. 2009). MACF also affects wound healing by inhibiting cell migration, due to the lack of 
microtubule networks targeting to focal adhesions, which prevents the cells from adhering to 
the extracellular matrix (Wu et al. 2008). These functions are important in the growth and 
development of muscle. Intact microtubule networks are required for proper myocyte 
functioning; for example in organelle transport where the myonuclei moves from the middle of 
the cell to the periphery during development (Wilson & Holzbaur 2012). MACF, in being the 
most ancestral (most related to ancestral spectraplakins) seems to also be one of the most 
essential plakin family members.  The MACF null mouse model has been demonstrated to be 
embryonic lethal (Chen et al. 2006; Wu et al. 2008) and this suggests that the role of MACF in 
embryonic development is widespread and mandatory.  This spectraplakin is highly expressed 
in the dermomyotome and the neural fold of 8.5 day old mouse embryos (Bernier et al. 2000), 
further underlining its important developmental function. 
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1.4.4. Plectin 
Plectin is another important structural protein that is prominent in skin and muscle 
tissue and is the most well characterized of all the plakin family members (Wiche 1989). Plectin-
null mice exhibit severe skin blistering of the limbs and, after nursing, blistering in the mouth, 
which is linked to inhibition of food intake and death shortly after birth (Andra et al. 1997; 
Ackerl et al. 2007). Plectin has binding activity with many elements of the cell which allow it to 
bolster the structural integrity of the cell such as Z-lines in muscle and various intermediate 
filaments (Wiche et al. 1984; Schröder et al. 1999; Hijikata et al. 1999). Without this 
reinforcement, the structural integrity of tissues is greatly compromised. Plectin contains a 
plakin repeat domain which, as mentioned in section 1.4.1, is comprised of modified spectrin 
repeats. Due to the absence of spectrin repeats (as plakin repeats are not strictly considered 
spectrin repeats), plectin is not classified a spectraplakin. Of the plakin family members, plectin 
is the only non-spectraplakin which contains an actin binding region in some variants of the 
protein which is composed of a calponin homology (CH) domain similar to that of other plakins 
(Fuchs et al. 1999; Rezniczek et al. 2003). In skin, some plectin isoforms have been found to 
interact with microtubules, destabilizing them (Valencia et al. 2013). As with other plakins, such 
as dystonin and plectin, transcript diversity is very high. There are 18 known plectin variants 
created through alternative splicing of 13 exons at the 5’ end, with almost no transcript 
diversity elsewhere in the gene (Fuchs et al. 1999). Plectins can be separated into three major 
classes based on their 5’ regions: mRNAs where there is one start codon compatible with the 
plectin reading frame, mRNAs where there are multiple upstream start codons, but translation 
begins at the first start codon compatible with the plectin reading frame, and mRNAs where the 
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first exon is non-coding and translation is not initiated at the first compatible start codon in 
exon 4, but instead begins in exon 6 (Rezniczek et al. 2003). 
1.4.5. Other plakin family members 
Given that the remaining plakin family members (desmoplakin, epiplakin, periplakin, 
envoplakin) have no actin binding activity, their binding activity is mediated partly though the 
plakin repeat domain, which binds to a variety of intermediate filaments (Leung & Liem 2001). 
For example, desmoplakin, a protein that is part of desmosomes, binds the desmosome to 
intermediate filaments such as keratin through its plakin repeat domain. Mutations in human 
desmoplakin cause a disruption in desmosome organization and keratin dysfunction which 
leads to a number of phenotypical abnormalities. These include hair with a “wooly” 
appearance, thick keratin plaques on the skin in areas of the body with high mechanical 
stresses (mostly hands and feet) as well as reduced structural integrity in heart muscle leading 
to heart failure in adolescence (Norgett et al. 2000). Because these plakin family members are 
not known to be expressed in skeletal muscle, details related to their expression profile and 
roles in other tissues will not be discussed in this current literature review.  
1.5. Plakin expression in muscle 
Plakins are expressed in many tissues including muscle. Skeletal muscles undergo 
significant mechanical stress during contraction and relaxation cycles and require a robust 
cytoarchitecture to maintain structural integrity. It is therefore not surprising that plakin 
crosslinking proteins such as dystonin, plectin and MACF are expressed in skeletal muscle 
(Boyer et al. 2010).  
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1.5.1. Dystonin 
The role of dystonin can be elucidated by studying muscle tissue of mutant dystonin (or 
dystonin-deficient) mice. There are a wide variety of dystonin mutations, all causing similar 
phenotypes of varying intensity. Examples of these mutations are dtTg4, dt24J, dt27J, dtAlb, , dtFrk, 
dttm1Efu (Ferrier et al. 2013). In these mice, Z-line organization is affected. The dysfunction that 
follows dystonin mutations implies that dystonin interacts with Z-lines, either directly or 
indirectly, to stabilize them in muscle (Dalpé et al. 1999). At the cellular level, dystonin 
deficiency is characterized by a decreased amount of myofibrils with disorganized arrangement 
at the Z-disk (Dalpé et al. 1999). In addition, mitochondria, normally dispersed throughout the 
muscle, are found in clusters near the sarcolemma in dystonin-deficient muscle, indicating 
functional binding with mitochondria (Dalpé et al. 1999). These structural deficiencies are 
manifested at the macroscopic level through dysfunctional muscle. The muscles of dystonin-
deficient mice show increased weakness, decreased fatigue resistance and are prone to 
contraction-induced damage (Dalpé et al. 1999). In general, dystonin is an important regulator 
of muscle cytoarchitecture and disruptions in dystonin cause severe muscle pathologies. 
1.5.2. MACF 
The role of MACF in development has already been outlined in section 1.4.3. In relation 
to muscle development in particular, a mutation of the short stop gene in Drosophila was 
shown to cause a disorganization of myotubes in muscle (Strumpf & Volk 1998). This was 
observed during Drosophila development where MHC staining to visualize myotubes showed 
severe disruption in the arrangement of muscle in mutant embyros relative to wild type 
embryos (Strumpf & Volk 1998).  In mice, MACF has been shown to be strongly expressed in 
muscle tissue of 13.5 day old embryos (Bernier et al. 2000). Given the similarity between MACF 
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and Short Stop, it is possible that MACF knockout mice would also display a similar muscle 
phenotype as reported in Drosophila. However, it would be necessary to generate a MACF 
knockout model that would permit the animals to survive past embryonic development to be in 
a position to investigate the impact of MACF suppression on postnatal muscle growth. 
Engineering MACF muscle-specific knockdown in mice would provide a useful model to study 
the potential functions of MACF in skeletal muscle during post-natal development. To our 
knowledge, conditional knockouts have been developed in neural tissue (Goryunov et al. 2010) 
and skin (Wu et al. 2008) but not in muscle. 
1.5.3. Plectin 
As previously mentioned, plectin contains numerous isoforms. The four isoforms which 
are most abundant in muscle are plectin 1, 1b, 1d and 1f (Castañón et al. 2013), with P1d being 
the only plectin variant exclusive to muscle (Fuchs et al. 1999). 
The following figure from (Castañón et al. 2013) provides an excellent summary of the 
various plectin variants in muscle and their function: 
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Figure 1-3: Graphical representation of the function of the four plectin isoforms present in 
muscle. Plectin 1 binds to the nucleus and to desmin. Plectin 1b links mitochondria to the 
desmin IF network. Plectin 1d crosslinks the Z-disk to the desmin IF network. Plectin 1f binds 
the dystroglycan complex to the desmin IF network. All these functions are crucial to the 
structural resilience in muscle required to resist the mechanical stresses present in 
contraction/relaxation cycles (taken from Castañón et al. 2013). 
 
Desmin is the most abundant intermediate filament found in skeletal muscle 
(Capetanaki et al. 2007) and all plectin isoforms in muscle bind to it at their C-terminal 
intermediate filament binding domain. These interactions provide the extensive structural 
support required for the mechanical function of muscle tissue. Conditional knockout of plectin 
in muscle disrupts the desmin intermediate filament (IF) network (Konieczny et al. 2008). The 
interaction of plectin isoforms with the desmin cytoskeleton is described below. 
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Plectin 1 binds the nucleus and the endoplasmic reticulum to the desmin IF network, as 
it was found concentrated near these structures in mouse quadriceps muscle and was very 
diffuse in other areas of the cell (Rezniczek et al. 2007). As such, plectin 1 is thought to 
contribute to cellular integrity. It has been known for some time that plectin links desmin and 
mitochondria (Reipert et al. 1999). More recently, it was found that plectin 1b specifically is the 
link between mitochondria and the desmin IF network. P1b inserts itself into the mitochondrial 
membrane deeply enough that it resists degradation by protease enzymes (Winter et al. 2008). 
P1b knockout mice exhibit none of the extreme effects of total plectin deficiency and appear 
identical to wild type mice externally. The only apparent effect is that the shape of 
mitochondria in the cells of these mice becomes elongated. This can be reversed with forced 
expression of P1b (Winter et al. 2008). 
P1d is the only plectin variant that is exclusively expressed in muscle (Fuchs et al. 1999). 
This is not surprising given it is only found in association with Z-disks (Rezniczek et al. 2007), 
which are structures unique to muscle. However, the mechanism by which P1d is targeted to Z-
disks has not yet been solved (Castañón et al. 2013). P1d along with P1f seem to be the most 
important for the structural integrity of muscle. P1d knockout mice, as well as P1f knockout 
mice, have a similarly severe phenotype to that of mice lacking all isoforms (Konieczny et al., 
2008, as cited in Castañón et al., 2013). This phenotype is characterized by decreased 
endurance, muscle with a pale appearance, aggregation of intermediate filaments, and Z-disk 
aggregation (i.e. forming clusters) (Konieczny et al. 2008). 
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Plectin 1f links the sarcolemma to the desmin IF network through the dystrophin 
glycoprotein complex; specifically, P1f binds to β-dystroglycan through its plakin domain, and to 
dystrophin via its actin binding domain (Rezniczek et al. 2007). When dystrophin is absent, 
plectin can also bind to β-dystroglycan with its actin binding domain, using a binding site 
normally occupied by dystrophin. This increases the amount of plectin localized at the 
sarcolemma in dystrophin-deficient mice (Rezniczek et al. 2007), a finding that is in line with 
previous results in muscle of Duchenne Muscular Dystrophy patients showing increased 
sarcolemmal plectin localization (Schroder et al. 1997). Plectin 1f also crosslinks desmin to 
acetylcholine receptors (AChR) at the neuromuscular junction (NMJ) at the sarcolemma 
(Mihailovska et al. 2014). Plectin knockout in immortalized myocytes was shown to cause AChR 
clusters to become more dispersed and disconnected from the desmin network (Mihailovska et 
al. 2014). 
The structural properties of plectin can affect muscle physiology. For example, P1f has 
been shown to be overexpressed and to accumulate near the sarcolemma in muscular 
dystrophy patients and in a mouse model of muscular dystrophy, known as mdx (Rezniczek et 
al. 2007). When plectin is knocked out in mdx mice, the sarcolemma is no longer compromised 
(Raith et al. 2013). Further, while glucose uptake in muscle is impaired in mdx mice due to the 
accumulation of plectin 1f near the sarcolemma, plectin deficiency in mdx mice alleviates the 
glucose uptake impairment (Raith et al. 2013). It is therefore apparent that there is an optimal 
expression level and positioning of plectin and other structural proteins such as dystrophin to 
finely tune various aspects of muscle function.  
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1.6. Nerve activity and its effect on muscle physiology 
The phenotype of skeletal muscle is highly regulated by signals from the innervating 
motor neuron. More specifically, the contractile properties of muscle fibers and their size are 
controlled by nerve-mediated activity and by neurotrophic molecules. Innervation also has a 
profound impact on gene expression in muscle cells, which governs the phenotype of skeletal 
muscle fibres (MacIntosh et al. 2006).  In the absence of nerve activity, the expression of 205 
genes is known to be differentially regulated in muscle (Magnusson et al. 2005). For instance, 
members of the myogenic regulatory factors, such as myogenin and MyoD, are significantly 
upregulated in inactivated muscles and the fact that manual electrical stimulation lessens this 
effect is further proof that neural activity itself is an important regulator of myogenin and 
MyoD gene expression (Eftimie et al. 1991).  
Some of the genes whose expression are affected by reduced neural input contribute to 
processes underlying muscle atrophy (Kandarian & Jackman 2006).  Muscle atrophy is a 
significant muscle condition associated with increased catabolic activity and decreased anabolic 
activity, with a net breakdown of protein resulting in a loss of muscle mass and force (Kandarian 
& Jackman 2006). Muscle atrophy in humans can be caused by inactivity, disease or aging 
(Kandarian & Jackman 2006). Many diseases can cause muscle atrophy including sepsis, renal 
failure, cancer (Hasselgren & Fischer 2001) and Amyotrophic Lateral Sclerosis (ALS) (Léger et al. 
2006).  
Muscle atrophy is the result of complex molecular processes involving many proteins 
(Powers et al. 2012; Glass 2005; Kandarian & Jackman 2006).  In various experimental models of 
atrophy involving animals, a large number of genes are differentially regulated. However, the 
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gene profile is not consistent across different animals and atrophy methods (Bodine et al. 
2001).  Examples of genes shown to be upregulated include Muscle Ring Finger 1 (MuRF1) and 
Heat Shock Protein 36 (HSP36) and some examples of downregulated proteins are lactate 
dehydrogenase and creatine kinase (Bodine et al. 2001). Heat Shock Protein 72 was also found 
to be downregulated in unloaded and denervated muscle (Oishi et al. 2001). In another study, 
Histone Deacetylase 4 (HDAC4) was found to be responsible for gene expression changes 
leading to atrophy in a muscle inactivity model (Cohen et al. 2007). Upon loss of neural activity, 
HDAC4, normally located near synapses, relocates to the nucleus and is significantly 
upregulated, which leads to the changes in expression of many genes such nicotininc 
acetylcholine receptors (nAChRs) and myogenin. Blocking HDAC4 expression reduces this effect, 
implying that HDAC4 is involved in this dysregulation (Cohen et al. 2007). 
1.6.1. Models of Muscle Atrophy 
Muscle atrophy can be induced experimentally in animal models through reduced 
neural input. Some researchers use hindlimb suspension (Thomason & Booth 1990; Lawler et al. 
2003). This experimental procedure utilizes a harness which elevates the hindlimb of the rats in 
a cage while still allowing them to move freely with the use of their forelimbs. This can be 
maintained for various periods of time and this type of muscle unloading causes muscle atrophy 
(Powers et al. 2014). In other studies, a plaster cast may be placed on the animal’s limb to 
restrict movement (Booth & Kelso 1973; Kelleher et al. 2013). This causes atrophy in a similar 
fashion to hindlimb suspension.  Muscle denervation is another, more severe model of muscle 
atrophy which will be discussed below.  
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 Muscle denervation is the suppression of neural impulses to the muscle by severing the 
nerve. This procedure is well described in the literature – the animals (often mice or rats) are 
first anesthetised and then the sciatic nerve is severed high in the thigh, as close as possible to 
the sciatic notch (Dow et al. 2004; Carlson & Faulkner 1988). The nerve may be simply cut, or a 
small (5-10mm) portion may be removed entirely (Dow et al. 2004; Carlson & Faulkner 1988). 
The denervation period for various studies can vary greatly – long term studies may wish to 
study denervation after 12 months (Adams et al. 1995) and short-term studies may examine 
denervation periods of as little as one day, with periods in between ranging from 1-3 months 
(Batt et al. 2006) or even 1-7 days (Boudreau-Larivière et al. 2000). 
Control measures are an important consideration in denervation studies. A non-
denervated rat may not be an appropriate control if the animal has not been exposed to 
physical stress such as anaesthesia and surgery. The control protocol for denervation, referred 
to as “sham”, is to anesthetise the animal and perform the surgery in an identical fashion to the 
denervated animals, stopping short of severing the nerve. In other words, the nerve is exposed 
but not severed (Yoshimura et al. 1999). This provides a control that is more appropriate for 
comparison. 
1.6.2. Effects of denervation 
Denervation leads to atrophy of muscle that is manifested by a reduction in cross-
sectional area of muscle fibers, a loss of muscle mass, and also a significant (almost total) loss of 
muscle force, after a sufficient period of time. After only two months of denervation, rat 
muscles can lose 69% of original mass and 98% of original force (Carlson & Billington 1996). 
After 22 months, muscles are atrophied to the point where their thickness is similar to that of 
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their tendons (Carlson & Faulkner 1988).  This clearly underlines the importance of nerve-
mediated muscle activity to maintain the health of the muscle tissue. 
Denervation seems to revert the muscle to an embryonic expression profile. For 
instance, during embryonic fetal development, before myocytes are innervated, nicotinic 
acetylcholine receptors are expressed throughout the muscle fiber. They are then repressed 
everywhere except the neuromuscular junction in mature myocytes (Sanes & Lichtman 2001) 
after the developing muscle in the fetus has been innervated. The nicotinic acetylcholine 
receptors (nAChR) expressed in embryonic myocytes are composed of different subunits than in 
mature myocytes, and denervation causes the expression of embryonic-type receptor subunits 
until about 1-2 months, where the mature receptor subunits begin to be expressed again 
(Adams et al. 1995). In this case, it seems that denervation causes the muscle to express 
proteins that are normally exclusively expressed in the developing embryo, for a limited 
amount of time.  The myogenic transcription factor myogenin, which is highly expressed during 
myotube differentiation, is virtually undetectable in the muscles of post-natal animals (Eftimie 
et al. 1991).  However in denervated muscles, myogenin expression is significantly upregulated 
(Hyatt et al. 2003; Eftimie et al. 1991) for a similar period of time as nAChR further highlighting 
the reversion of muscle to an embryonic state upon denervation (Adams et al. 1995)  
A variety of proteins are differentially expressed in muscle following denervation (Tang 
et al. 2000). These include calpain-3, TNF Type 1 receptor associated protein (TRAP-2), Pre-B 
cell enhancing factor (PBEF), Muscle specific enolase (MSE), Myosin heavy chain IIb (MHCIIb) as 
well as Glutamine synthetase (GS) (Tang et al. 2000). Denervation was also shown to have an 
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effect on the expression of various structural elements in muscle. For example, desmin, an 
abundant intermediate filament which was discussed above, was shown to be upregulated in 
denervated rat facial muscle after two weeks, although after seven weeks expression levels of 
desmin returned to normal (Tews et al. 1997). Desmin was also shown to be upregulated in 
denervated rat gastrocnemius muscle as was tubulin (Boudriau et al. 1996). The large structural 
protein titin was differentially regulated in denervated skeletal muscle (Chen et al. 2005). It was 
shown to be downregulated by 4% starting at 7 days post denervation with a 25% reduction 
observed after 56 days of denervation. In contrast, dystrophin as well as β-dystroglycan, 
components of the dystroglycan complex discussed earlier, are upregulated following 
denervation. This upregulation coincides with the increased expression and reappearance of 
acetylcholine receptors within extra-synaptic regions of the sarcolemma following denervation 
(Biral et al. 1996).  How denervation impacts the expression of other structural proteins such as 
plakin crosslinking proteins in skeletal muscle is currently not fully understood. 
1.7. Statement of the problem  
 Plectin, dystonin and MACF are plakin crosslinking proteins that are expressed in 
skeletal muscle. These proteins play a critical role in organizing the cytoskeleton and 
crosslinking organelles and the cell membrane to intermediate filaments in various tissues, 
including muscle. Muscle tissue is a force generating tissue that is highly influenced by neural 
activity. An absence of neural activity has been shown to cause dysregulation of many genes 
within the muscle. The expression patterns of plectin, dystonin and MACF in muscle during 
denervation-induced atrophy is poorly understood. Specifically, it is not known whether these 
muscle plakins are differentially expressed at the protein or mRNA level in this model, and if 
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they are, whether they are downregulated or upregulated. As a whole, the findings of the 
present research are anticipated to further our understanding of the impact of innervation on 
muscle plakin expression in skeletal muscle. 
1.8. Hypotheses 
The three hypotheses tested were: 
1) MACF will be upregulated in denervated muscle at the mRNA and protein level. 
2) Dystonin will be downregulated in denervated muscle at the mRNA and protein level. 
3) Plectin will be downregulated in denervated muscle at the mRNA and protein level. 
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Chapter 2 
2. Materials and Methods 
2.1. Mouse information and denervation procedure 
Two-month old male CD1 mice were purchased from Charles River Laboratories (Saint-
Constant, Québec) and were kept in plastic shoebox cages in groups of 4-5 mice per cage. Mice 
had access to food and water ad libitum, and were exposed to a 12 hour light/dark cycle in a 
climate controlled room (23±2°C). Animals were treated in accordance with the Canadian 
Council on Animal Care guidelines. This study was approved by the Laurentian University 
Animal Care Committee (see Appendix D for approval certificate). 
Mice were anesthetised using isoflurane (5% for induction 1-3% for maintenance) with a 
3:1 mix of air to oxygen The skin overlying the sciatic nerve was shaven and cleaned using 
hibitane and iodine. Denervation was performed under aseptic conditions. Mice were 
denervated unilaterally by severing the sciatic nerve near the hip area. The opposite limb was 
sham-denervated; these limbs had their sciatic nerve exposed, but it was not severed.  Mice 
were then sutured with sterile clips and left to recover. The denervation status was confirmed 
by the absence of the toe pinch, toe spread and plantar flexion reflexes.  All three of these 
reflexes were evident in the sham limb (i.e. non-denervated). After 1, 3, 7 or 14 days, mice were 
anesthetized with a xylazine (10 mg/kg bodyweight) and ketamine HCl (100mg/kg bodyweight) 
mix and the gastrocnemius skeletal muscles were carefully harvested from the denervated and 
sham hindlimb and quickly frozen in liquid nitrogen. Muscle samples were stored at -80oC until 
further use. 
24 
 
2.2. Sample preparation 
Mouse gastrocnemius muscles were divided in half; one half was processed for RNA 
extraction and the other half for protein isolation. For RNA isolation, TRIzol (Life Technologies, 
Gaithersburg, MD) was used as per manufacturer’s instructions. RNA pellets were resuspended 
in RNase-free water then frozen at −80oC until further use.  For protein isolation, muscle 
samples were homogenized in radioimmune precipitation assay (RIPA) buffer supplemented 
with protease inhibitors (RIPA: 150mM sodium chloride, 1.0% v/v Triton X-100, 0.5% w/v 
sodium deoxycholate, 0.1% w/v sodium dodecyl sulphate, 50mM Tris, pH 8.0; protease 
inhibitors: 2μg/ml aprotinin, 10μg/ml leupeptin, 1μg/ml Pepstatin A, 1mM PMSF, 5mM EDTA, 
1mM EGTA, 10mM Sodium Fluoride, 1mM sodium orthovanadate).  300 μL of RIPA buffer was 
used per 25mg of tissue. To homogenize muscle, a tissue tearor (Biospec products, Bartsville, 
USA) was used in 15 second pulses until sample was homogenous. Samples were then 
incubated at 4°C for 4 hours under constant agitation and then centrifuged (12,000RPM at 4°C) 
for 20 minutes. The supernatant from each sample was collected and stored at -80oC until 
further use.  
RNA and protein concentration for each sample was then determined.  RNA was 
quantified by diluting an aliquot in TE buffer and measuring the absorbency at 260/280nm 
wavelengths using a spectrophotometer. The 260/280 ratio was used to assess phenol/protein 
contamination. Our samples were deemed of sufficient quality (contaminant-free) to proceed 
with analysis. RNA concentration was calculated based on the conversion factor of 1 unit 
absorbency equaling 40µg/ml of RNA. Aliquots of the RNA samples were then run on an 
ethidium-bromide stained agarose gel to determine the integrity of the samples and to ensure 
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that no degradation had occurred during the isolation procedure (see Figure 2-1 for a 
representative example). RNA integrity was deemed of acceptable quality when the 28S and 
18S ribosomal RNA bands were clearly evident with no observable smearing and when the 28S 
band was roughly twice as intense as the 18S band (see Appendix A for all RNA agarose gels).  
 
Figure 2-1: RNA integrity gel. Shown are three representative den/sham sample pairs from 
mice 115, 116 and 117. The clear 28S (top) and 18S (bottom) bands demonstrate that the RNA 
is not degraded. For additional information see Appendix A. 
 
Protein lysate concentrations were quantified using the Bio-rad Detergent Compatible 
(DC) protein assay (Bio Rad, Missisauga, Canada) on a 96 well microplate using a 1:7 sample 
dilution. The procedure was performed according to manufacturer’s instructions and read on a 
Biotek Powerwave-X Microplate reader at 750nm (Biotek, Ottawa, Canada). Final protein 
concentrations were determined from a standard curve generated from BSA samples with 
known concentrations processed in parallel. Regression analysis of the absorbency data was 
performed using the KC Junior software (Biotek, Ottawa, Canada). 
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2.3. Immunoblot analysis 
8 protein samples from each time point (1, 3, 7 and 14 day) were separated on each gel 
(4% stacking, pH 6.8; 4% resolving, pH 8.8). This included 4 denervated (den) samples and their 
4 contralateral control (sham) muscles. In total, 8 muscles along with the corresponding 8 
contralateral controls were processed for each time point. 100ug of the protein lysates were 
resolved on SDS/4% polyacrylamide gels (SDS-PAGE) along with a HiMark pre-stained protein 
ladder (Life Technologies LC5699). Samples were treated with Laemmli’s Buffer (63mM Tris HCl, 
10% (v/v) Glycerol, 2% (w/v) SDS, 0.0025% (w/v) bromophenol blue, pH 6.8, 5% ß-
Mercaptoethanol (v/v)) and heated at 100°C for five minutes then cooled for five minutes, on 
ice, prior to loading. Acrylamide gels were electrophoresed for 120 minutes in SDS 
electrophoresis buffer (25mM Tris base, 190mM Glycine, 0.1% w/v SDS) then were transferred 
onto a polyvinylidene fluoride (PVDF) membrane (0.45μM pore size, Millipore corporation, 
Billerica, USA) in transfer buffer (25mM Tris base, 190mM Glycine, 15% v/v methanol). 
Membranes were then blocked for one hour in 5% w/v milk in Tween Tris-buffered Saline 
(TTBS) (50mM Tris, 150mM NaCl, 0.05% v/v Tween 20, pH 7.6) and then incubated with either 
mouse mono-clonal plectin (Santa Cruz sc-33649), polyclonal rabbit dystonin (Sigma Genosys, 
custom) and mouse mono-clonal MACF (Santa Cruz sc-68430) antibodies at 1:200 dilution in 5% 
milk in TTBS overnight at 4°C under constant agitation. Membranes were then washed in 3 
separate 10 minute TTBS washes then incubated with the corresponding goat anti-mouse  
(Santa Cruz sc-2005) or anti-rabbit (Santa Cruz sc-2030) secondary antibodies conjugated to 
horseradish peroxidase at a dilution of 1:50000 in 5% milk in TTBS at room temperature for 30 
minutes on a rocking platform (Model 200, VWR scientific) then washed again (3x10 minute 
washes in TTBS), and subsequently developed with Enhanced Chemi Luminescence (ECL) 
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reagents (GE healthcare RPN2232). Membranes were stripped of antibodies and re-probed 
after each immunoblotting experiment, and stripped a final time before staining the membrane 
with Coomassie brilliant blue to verify protein loading to be used as a loading control. Stripping 
was performed by incubating the membrane in stripping buffer (1% SDS (w/v), 0.8% ß-
Mercaptoethanol (v/v) and 0.0625 Tris HCl, pH 6.8) under light agitation at 50°C for 30 minutes 
then thoroughly rinsing the membranes with distilled water before washing 3x15 minutes in 
TBS-T. The membrane was then blocked, incubated with secondary antibody and imaged with 5 
minute exposures to ensure lack of signal. The membranes were imaged using the 
ChemidocXRS machine (Bio-rad, Missisauga, Canada). Densitometry analysis was performed 
using QuantityOne software (Bio-rad, Missisauga, Canada) by outlining the bands and 
subtracting the background intensity from the average band intensity. 
2.4. Quantitative PCR Analysis 
RNA was first reverse transcribed using the Qiagen QuantiTect Reverse Transcription kit, as per 
manufacturer’s instructions. For PCR analysis, the Qiagen QuantiTect Primer Assay was used 
with the following primers: actin (QT00095242), plectin (QT00288589), myogenin 
(QT00112378), acetylcholinesterase (AChE; QT00287357), dystonin (QT01771308), tubulin 
(QT00116319), MACF (QT00243670), and ribosomal protein S12 (RPS12; QT00317317) as per 
manufacturer’s instructions. AChE and myogenin were used as positive denervation controls, as 
marked downregulation (AChE) and upregulation (myogenin) have been shown to occur 
following denervation (Eftimie et al. 1991; Sketelj et al. 1998; Boudreau-Larivière et al. 2000). 
Actin, tubulin and RPS1 were included as potential internal control candidates, since mRNAs 
with stable expression following denervation are required to normalize expression levels of 
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target mRNAs. 8 denervated samples from each (1, 3, 7 and 14 day) time point, along with the 
corresponding contralateral control sample, were loaded in duplicate onto 96 well plates, 
incubated at 95°C for 15 minutes followed by 40 cycles of denaturation at 94°C for 15s, 
annealing at 55°C for 30s and extension at 72°C for 30s in a PTC-200 thermal cycler equipped 
with a Chromo4 Real Time PCR instrument (MJ Research). Every 96 well plate also included a 
standard curve created using serial dilutions, each in triplicate, of a complementary DNA 
(cDNA) sample of known concentration. The data was collected using the Opticon Monitor 
software (MJ Research) and a C(t) score standard curve equation was created to extrapolate 
the abundance of the target mRNA in the denervated versus the control sham samples over the 
denervation time course. The C(t) score ranges for all samples and standard curves are shown 
in Table I. PCR efficiency ranged between 75-105%. PCR data was normalized to RPS12 as it was 
considered to be the most reliable (i.e. stably expressed in SHAM vs DEN samples) internal 
control (see Figure 2-2). Quantitative PCR data was expressed as a ratio of normalized den to 
normalized sham samples, where a den/sham ratio greater than 1 indicates an upregulation 
following denervation, and a den/sham ratio less than 1 indicates downregulation following 
denervation. 
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Table I: C(t) score range for the standard curve and the experimental samples. Two plates 
were run for each primer tested and these are shown separately. The majority of samples were 
within the range of the standard curve. 
 
Plate 1 Plate 2 
 
Std. 
Curve 
Min 
Std. 
Curve 
Max 
Samples 
Min 
Samples 
Max 
Std. 
Curve 
Min 
Std. 
Curve 
Max 
Samples 
Min 
Samples 
Max 
AChE 20.82 34.76 21.79 29.94 20.75 34.29 23.04 31.35 
Actin 21.65 36.24 15.20 23.79 15.98 31.65 19.24 24.83 
Dystonin 16.24 33.46 19.28 24.00 15.58 30.94 17.87 22.64 
MACF 17.23 31.27 19.17 27.53 15.83 33.26 20.65 25.65 
Myogenin 19.54 30.86 12.23 24.35 17.16 32.03 21.05 30.04 
Plectin 15.94 35.02 18.21 23.83 15.57 32.60 18.83 23.04 
RPS1 14.30 30.33 17.15 20.72 14.42 30.28 17.92 20.79 
Tubulin 17.33 31.55 19.19 23.89 17.63 32.01 20.72 26.96 
 
2.5. Data analysis 
Data was analyzed in SPSS. Outliers were removed according to default SPSS settings for 
outliers, defined as 1.5 times the interquartile (Q3-Q1) range below the first and above the 
third quartile. Data was checked for normality and when the test for normality failed, the data 
was log-transformed and re-checked for normality. When this improved normality, log-
transformed data was used for analysis. This was the case for MACF, dystonin and AChE for 
mRNA data and for MACF for protein data. An analysis of variance (ANOVA) was used to 
determine differences between den/sham pairs across the four time points for each of eight 
data sets (plectin, dystonin, MACF, myogenin and AChE mRNA as well as plectin, dystonin and 
MACF protein expression) and paired t-tests were used to assess the difference between 
den/sham pairs within each time point for each of the eight data sets above.  The significance 
threshold was set at p<0.05. 
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Figure 2-2: Comparison of four potential normalization candidates for qPCR data. Data are 
expressed as Means ± SD (n = 8 for den/sham ratio for each time point). A ratio equivalent to 1 
is indicative of similar expression levels in the den and sham muscle samples.  A) Actin 
den/sham ratios over the four denervation time points. Actin expression is fairly stable 
between the den and sham muscles at days 1, 3 and 14 but extremely variable at day 7. B) 
Tubulin expression is similar to actin, with high variability at day 7 but also increased variability 
at day 14. C) RPS12 was the most stable of all three potential normalization candidates with 
minimal variance. D) The den/sham ratios for Actin, Tubulin and RPS12 were collapsed and the 
means and SD were calculated. The higher variability at day 7 persisted.  Based on these results, 
RPS12 was selected as the normalization control for the qPCR analyses because the ratios were 
closest to one with minimal variance.   
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Chapter 3 
3. Results 
3.1. Markers of denervation  
To ascertain whether the denervation procedure was successful, the following three 
reflexes were monitored on a daily basis in both the sham and den hindlimb: toe spread, toe 
pinch and plantar flexion.  In all instances these reflexes were present in the sham hindlimb and 
absent in the den hindlimb.  Furthermore, we monitored the gastrocnemius hindlimb muscle 
mass as well as the gene expression levels of myogenin and AChE which are both known to be 
significantly upregulated and downregulated respectively in denervated skeletal muscle 
(Eftimie et al. 1991; Boudreau-Larivière et al. 2000; Sketelj et al. 1998).  
 Frozen mouse gastrocnemius muscles were weighed (in milligrams) and these values 
were normalized to total bodyweight of each mouse (in grams). These values are reported in 
Table II and displayed in Figure 3-1.  As anticipated, significant muscle atrophy was observed in 
denervated hindlimb muscles as revealed by paired t-tests.  In particular, normalized muscle 
mass had decreased by 6.6% after only 24 hrs of denervation (p=0.006), by 9.3% after 3 days of 
denervation (p=0.011), by 23.1% after 7 days (p<0.001) and by 41.5% after 14 days of 
denervation (p<0.001). In comparison, the left and right gastrocnemius muscles of control mice, 
which were anesthetized but did not undergo surgery, had nearly identical muscle mass 
(p=1.000) thereby indicating that our excision technique was consistent. 
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Table II. Mouse gastrocnemius mass (mg) normalized to body weight (g). Data are presented 
as Means ± SE (mg/g) (n = 10 for sham and den at each time point, n = 4 for control mice). 
 Day 1 Day 3 Day 7 Day 14 Control 
Sham 4.8±0.10 4.7±0.11 4.8±0.08 4.8±0.10 4.4±0.32 
Den 4.5±0.09 4.3±0.08 3.7±0.09 2.8±0.11 4.4±0.28 
% change -6.6% -9.3% -23.1% -41.5% 0.2% 
p-value 0.006 0.011 <0.001 <0.001 1.000 
 
 
Figure 3-1: Impact of denervation on mouse Gastrocnemius muscle weight. Data are 
expressed as muscle weight normalized to body weight (Means ± SE). (n = 10 for sham and den 
mice, for each time point, n = 6 for control). Paired samples t-tests revealed statistically 
significant atrophy after 24 hours of denervation (7% reduction, p=0.006). Atrophy 
progressively worsened at every time point, leading to a 42% loss in muscle mass after two 
weeks of denervation (p<0.001). No significant difference was found between the right and left 
hindlimb muscle weights of non-denervated mice (Control). 
33 
 
An ANOVA was performed on the den/sham ratios for muscle weight to determine if there 
were statistically significant differences at the four denervation time points (Figure 3-2). The 
ANOVA was significant (F4,45=17.293, p<0.000) and Tukey’s post hoc tests were used to 
determine differences between groups. Days 7 and 14 were significantly lower than days 1, 3 as 
well as the control group. No other significant differences existed between groups. 
 
Figure 3-2: ANOVA of den/sham ratio of mouse muscle weight following 1, 3, 7 and 14 days of 
denervation. Data are expressed as a ratio of normalized muscle weight in den vs sham muscles 
(Means ± SE) (n = 10 for den/sham ratio for each time point, except for control where n=6). 
Days 7 and 14 were significantly lower than day 1 (a), day 3 (b) and control (c) time points. No 
other significant differences existed between groups. 
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Next, we measured the gene expression levels of myogenin and AChE in sham versus 
den skeletal muscle at the same four denervation time-points using qPCR.  Expression levels for 
sham samples were set to a value of 1 for myogenin and the expression levels in the 
denervated samples were calculated as a ratio of den/sham.  These data are presented in Table 
III as well as in Figure 3-3 through Figure 3-6.  Paired t-tests were performed to analyze the 
difference between myogenin mRNA expression levels in den muscle compared to their 
respective contralateral sham controls. After 1 day of denervation, myogenin expression in den 
muscle was substantially increased by 9-fold in comparison to sham muscle (p=0.016). After 3, 7 
and 14-days of denervation, high levels of expression for myogenin were maintained; 
approximately 9-fold (p=0.001), 12-fold (p=0.019) and 13-fold (p=0.059) respectively.  An 
ANOVA was performed on the den/sham ratios to determine if there were statistically 
significant differences in myogenin expression levels at the four denervation time points (Figure 
3-4). This analysis revealed that myogenin induction occurred very early in the denervation time 
course and was sustained over the two-week period post-denervation (F3,27=0.543, p=0.657). 
Table III. mRNA expression of myogenin and AChE in sham and denervated muscles after 1, 3, 
7 and 14 days of denervation as assessed by qPCR. Den values were normalized to a sham 
value of 1. Data are Means + SE (Arbitrary unit). (n = 8 for sham and den mice for each time 
point). An asterisk denotes significant difference between sham and den at each time point. 
 Myogenin AChE 
 Sham Den Sham Den 
Day 1 1.0±0.30 9.3±2.86* 1.0±0.22 0.39±0.065* 
Day 3 1.0±0.29 9.5±1.72* 1.0±0.21 0.14±0.024* 
Day 7 1.0±0.21 11.6±3.53* 1.0±0.17 0.16±0.044* 
Day 14 1.0±0.29 13.4±5.73* 1.0±0.29 0.12±0.056* 
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Figure 3-3: Impact of denervation on myogenin mRNA expression levels. Data are expressed 
as Means ± SE with den samples being normalized to a sham value of 1. (n = 8 for sham and den 
mice for each time point). Paired samples t-tests revealed statistically significant upregulation 
after 24 hours of denervation (9-fold increase, p=0.016). This increase was maintained during 
the following 3, 7 and 14 days of denervation, with a moderate increase in magnitude paired 
with higher variance at later time points.  
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Figure 3-4: Impact of denervation on myogenin mRNA expression levels. Data are expressed 
as a ratio of mRNA levels in den vs sham muscles (Means ± SE) (n = 8 for den/sham ratio for 
each time point). After 24 hours of denervation, expression in den samples increased tenfold 
relative to sham samples. This upregulation is fairly stable between 1 and 14 days. ANOVA 
revealed no statistically significant differences in myogenin expression levels between any of 
these time points. 
  
37 
 
AChE expression was normalized to a sham value of 1 and these data are presented in 
Table III. Paired t-tests were performed to analyze the difference between AChE mRNA 
expression levels in denervated muscle and their contralateral sham controls. Paired t-test 
results are presented in Figure 3-5. One day after denervation, AChE expression in denervated 
muscle was reduced by 60.9% compared to sham muscle and this difference was significant 
with p=0.033. AChE expression in denervated muscle was reduced by 85.8% after 3 days 
(p=0.003) then remained fairly stable with an 84.4% reduction at day 7 and an 87.6% decline at 
day 14 (p<0.001 and p=0.011, respectively).  An ANOVA was performed on the den/sham ratios 
to determine if statistically significant differences existed between AChE expression levels at 
the four denervation time points (see Figure 3-6). The ANOVA was significant (F3,28=10.816, 
p<0.001) and Tukey’s post-hoc tests were performed to analyze the differences between time 
points. AChE expression levels at days 3, 7 and 14 were significantly decreased compared to 
Day 1 (p<0.001), but the den/sham expression ratios between days 3, 7 and 14 were not 
significantly different from each other. 
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Figure 3-5: Impact of denervation on AChE mRNA expression levels. Data are expressed as 
Means ± SE with den samples being normalized to a sham value of 1 (n = 8 for sham and den at 
each time point). Paired samples t-tests revealed statistically significant downregulation after 
24 hours of denervation (61% reduction, p=0.033). AChE expression levels appear to stabilize 
after 3 days with a downregulation of approximately 85% in denervated muscle after 3, 7 and 
14 days of denervation. 
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Figure 3-6: Impact of denervation on AChE mRNA expression levels. Data are expressed as a 
ratio of mRNA levels in den vs sham muscles (Means ± SE) (n = 8 den/sham ratio at each time 
point). Bars marked with an asterisk indicate values are significantly different from Day 1 
expression levels. After 24 hours of denervation, expression in den samples is reduced relative 
to sham samples. Between days 3 and 14, expression is reduced to 10-15% in den samples 
relative to sham samples. These latter time points are also significantly different from day 1 
expression ratios.  
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Collectively, the muscle weight and myogenin/AChE gene expression level data are in 
line with the anticipated phenotype of denervated skeletal muscle.  We therefore proceeded to 
measure the expression profile of the three plakin family members both at the mRNA and 
protein levels to better understand how these cytoskeletal proteins are impacted in skeletal 
muscles that have been inactivated subsequent to motor neuron injury. 
3.2. Gene expression of plectin, dystonin and MACF in denervated skeletal 
muscle 
3.2.1. Plectin 
Using the same cDNA samples processed for qPCR experiments to measure myogenin 
and AChE expression, we determined the gene expression levels of plectin.  Paired t-tests were 
performed to analyze the difference between plectin mRNA expression levels in den muscle 
and their contralateral sham controls (See Table IV and Figure 3-7 for paired t-test results). 
Plectin mRNA levels were slightly downregulated in den muscle at day 1 (11.1% reduction) and 
day 3 (26.0% reduction) but these differences were not significant at the α<0.05 significance 
threshold. After seven days of denervation, plectin expression was reduced by 45.7% (p=0.019) 
in den muscle and after 14 days expression was reduced by 57.5% (p<0.001). 
An ANOVA was performed on the den/sham ratios to determine if any statistically 
significant differences existed between plectin mRNA expression levels at the four, denervation 
time points. These results are presented in Figure 3-10. The ANOVA was significant (F3,28=3.651, 
p=0.024) and Tukey’s post hoc analysis revealed that Day 14 den/sham expression ratios were 
significantly lower than day 1 den/sham expression ratio, but no other significant differences 
existed between groups.  
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Table IV. mRNA expression of plectin, dystonin and MACF in sham and den muscles after 1, 3, 
7 and 14 days of denervation as assessed by qPCR. Den values were normalized to a sham 
value of 1. Data are mean + SE (n = 8 for sham and for den for each time point). An asterisk 
indicates significant differences from sham at that time point. 
 Plectin Dystonin MACF 
 Sham Den Sham Den Sham Den 
Day 1 1.0±0.22 0.9±0.21 1.0±0.18 1.0±0.17 1.0±0.28 0.8±0.24 
Day 3 1.0±0.21 0.7±0.18 1.0±0.21 0.7±0.16 1.0±0.27 2.1±0.53* 
Day 7 1.0±0.13 0.5±0.04* 1.0±0.12 0.5±0.04* 1.0±0.14 2.6±0.40* 
Day 14 1.0±0.07 0.4±0.03* 1.0±0.07 0.5±0.07* 1.0±0.09 2.1±0.43* 
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Figure 3-7: Impact of denervation on plectin mRNA expression levels. Data are expressed as 
mean ± SE with den samples being normalized to a sham value of 1 (n = 8 for sham and for den 
for each time point). Paired sample t-tests revealed statistically significant downregulation after 
7 days (45.7% decrease, p=0.019) and 14 days (57.5% decrease, p<0.001) of denervation. 
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3.2.2. Dystonin 
Paired t-tests were performed to analyze the difference between dystonin mRNA 
expression levels in den muscle and their contralateral sham controls (See Figure 3-8 and Table 
IV for paired t-test results). Dystonin mRNA expression patterns were similar to plectin, with 
small but non-significant reductions at day 1 (0.8% reduction, p=0.963) and day 3 (29.3% 
reduction, p=0.090) with more pronounced downregulation at day 7 and day 14. After seven 
days of denervation, dystonin expression was reduced by 45.8% in denervated muscle 
compared to sham controls and this difference was significant (p=0.010). After 14 days, 
expression was reduced by 49.4% (p<0.001). 
An ANOVA was performed on the den/sham ratios to determine if any statistically 
significant differences existed between dystonin expression levels at the four, denervation time 
points and these results are presented in Figure 3-10. Again, the pattern was very similar to that 
of plectin. The ANOVA was significant (F3,28=4.619, p=0.010) and Tukey’s post hoc tests revealed 
significantly lower expression at days 7 and 14 compared to day 1 (p=0.033, p=0.009 
respectively).  
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Figure 3-8: Impact of denervation on dystonin mRNA expression levels. Data are expressed as 
mean ± SE with den samples being normalized to a sham value of 1 (n = 8 for sham and for den 
for each time point). Paired sample t-tests revealed statistically significant downregulation after 
7 (45.8% decrease, p=0.010) and 14 days (49.4% decrease, p<0.001) of denervation. 
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3.2.3. MACF 
Paired t-tests were performed to analyze the difference between MACF mRNA 
expression levels in denervated muscle and their contralateral (sham-denervated) controls (See 
Figure 3-9 and Table IV for paired t-test results). MACF expression after 1 day was unaltered 
(p=0.494). However, after three days of denervation, expression in the den limb increased 
roughly twofold (112.0% increase, p=0.006). Expression then peaked after seven days of 
denervation with approximately a 2.5 fold (155.3%, p=0.016) increase in expression in den 
muscle compared to sham controls. After 14 days, expression returned to day 3 levels with a 
112.9% increase (p=0.030). 
An ANOVA was performed on the den/sham ratios to determine if any statistically 
significant differences existed between MACF expression levels at the four denervation time 
points. These results are presented in Figure 3-10. The ANOVA was significant (F3,27=4.709, 
p=0.009) and Tukey’s post hoc tests show that the Den/Sham expression ratios for MACF were 
significantly increased at day 3, day 7 and day 14 compared to day 1 (p<0.05). 
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Figure 3-9: Impact of denervation on MACF mRNA expression levels. Data are expressed as 
mean ± SE with den samples being normalized to a sham value of 1 (n = 8 for sham and for den 
for each time point). Paired sample t-tests revealed statistically significant upregulation 
beginning at day 3 (2-fold increase, p=0.006) and persisting through day 14 (2-fold increase, 
p=0.030), with a peak in expression at day 7 (2.5-fold increase, p=0.016). 
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Figure 3-10: Impact of denervation on plectin, dystonin and MACF mRNA expression levels. 
Data are expressed as a ratio of mRNA levels in den vs sham muscles (mean ± SE) (n = 8 for 
den/sham ratio for each time point). Bars marked with an asterisk indicate values that are 
significantly different from Day 1 expression levels relative to each plakin target. Both plectin 
and dystonin gene expression were progressively reduced over the denervation time course. By 
Day 14, mRNA levels for plectin and dystonin were reduced by half compared to Day 1 levels. In 
contrast, MACF gene expression was significantly upregulated at Days 3, 7 and 14 relative to 
Day 1, with expression in den muscle peaking at roughly 3 times the expression levels in the 
contralateral sham limb. 
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3.3. Protein expression of plectin, dystonin and MACF in denervated skeletal 
muscle 
3.3.1. Plectin 
Protein levels were determined by ‘high molecular weight’ Western blotting.  Paired t-
tests were performed to analyze the difference between plectin protein expression levels in 
den muscle and their contralateral sham controls. The results of the Paired t-tests are depicted 
in Figure 3-11 as well as in Table V.  Overall, the protein levels for plectin remained similar 
between the sham and den samples over the course of the denervation time course.  An 
ANOVA performed on the den/sham ratios also revealed that the ratios were similar over the 
course of the denervation time course (F3,24=0.640, p=0.597, see Figure 3-12).  
3.3.2. Dystonin 
Paired t-tests were performed to analyze the difference between dystonin protein 
expression levels in den muscle and their contralateral sham controls (see Figure 3-11 and Table 
V for results).  Dystonin expression was unchanged after one day and three days of denervation 
(p=0.857, p=0.077 respectively).  In comparison, dystonin was significantly upregulated after 
seven days (50.2% increase, p=0.019) and fourteen days of denervation (30.5% increase, 
p=0.005). 
An ANOVA was performed on the den/sham ratios and the results are summarized in 
Figure 3-12 and Table V. The ANOVA was significant (F3,28=5.083, p=0.006) and Tukey’s post hoc 
tests revealed that den/sham expression ratios for dystonin at days 7 and 14 were significantly 
increased from day 1 (p=0.014 and p=0.017, respectively). No other significant differences were 
found between time points. 
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3.3.3. MACF 
Paired t-tests were performed to analyze the difference between MACF protein 
expression levels in den muscle and their contralateral sham controls (see Figure 3-11). MACF 
expression was unchanged at day 1 (p=0.774) and at day 3 post denervation (p=0.059). After 
seven days, expression was transiently upregulated (67.4% increase, p=0.002) but returned to 
sham levels by day 14 (p=0.246). 
Results from an ANOVA performed on the den/sham ratios are summarized in Figure 
3-12. The ANOVA was significant (F3,28=4.663, p=0.009). Tukey’s post hoc tests revealed that 
MACF expression at day 7 was significantly upregulated compared to days 1, 3 and 14 (p<0.05); 
no other significant differences were found between time points. 
 
Table V. Plectin, dystonin and MACF protein expression in sham and den muscles after 1, 3, 7 
and 14 days of denervation as assessed by densitometry. Den values were normalized to a 
sham value of 1. Data are expressed as the mean +/- SE (n = 8 for sham and for den for each 
time point, except plectin day 1 where n=6 due to removal of outliers). An asterisk indicates 
significant differences between sham at that time point. 
 Plectin Dystonin MACF 
 Sham Den Sham Den Sham Den 
Day 1 1.0±0.44 0.9±0.22 1.0±0.27 0.9±0.25 1.0±0.08 0.9±0.15 
Day 3 1.0±0.13 1.2±0.20 1.0±0.04 1.2±0.04 1.0±0.21 1.1±0.20 
Day 7 1.0±0.26 1.6±0.39 1.0±0.25 1.5±0.42* 1.0±0.29 1.7±0.22* 
Day 14 1.0±0.24 1.2±0.31 1.0±0.04 1.3±0.06* 1.0±0.16 1.1±0.18 
 
  
50 
 
 
Figure 3-11: Impact of denervation on plectin, dystonin and MACF protein expression levels. 
Densitometry data presented in panels A, B and C are expressed as mean ± SE with den samples 
being normalized to a sham value of 1 (n = 8 for sham and for den for each time point, except 
plectin day 1 where n=6 due to the removal of two outliers). A) For plectin, paired samples t-
tests were performed and no statistically significant differences in protein levels were found at 
any time point. B) For dystonin, a moderate upregulation was noted at day 7 (50% increase, 
p=0.019) and persisted through day 14 (30% increase, p=0.005). C) For MACF a statistically 
significant upregulation was found at day 7 (67.4% increase, p=0.002) but this increase was 
transient as protein expression levels were not found to be significant at day 14 (7.8% increase, 
p=0.246). D) Examples of Day 14 immunoblots for plectin, dystonin and MACF, with sham 
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samples on the right and corresponding den samples to the left. The line to the left of each blot 
indicates the location of the 460kDa band. All other immunoblots are displayed in Appendix B. 
 
Figure 3-12: Impact of denervation on plectin, dystonin and MACF protein expression levels. 
Data are expressed as a ratio of protein levels in den vs sham muscles (mean ± SE) (n = 8 for 
den/sham ratio for each time point, except plectin where n = 6 due to the removal of outliers). 
Bars marked with an asterisk indicate values that are significantly different from Day 1 
expression levels. Bars marked with a diamond indicate values that are significantly different 
from Day 7 expression levels. No statistically significant differences were observed for plectin 
protein expression between all denervation time points. Dystonin protein expression was 
slightly higher at days 7 and 14 post-denervation compared to Day 1 expression levels but the 
ratios were less than 1.5.  MACF protein levels were significantly upregulated at day 7 but this 
increased expression was only transient as protein levels returned to sham levels at day 14 
post-denervation.  
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Chapter 4 
4. Discussion 
The main objective of this study was to determine how the gene expression of muscle 
plakin family members (dystonin, plectin and MACF) is impacted by neuromuscular inactivation.  
We used the denervation model which is the most extreme model of inactivation because it 
ensures that all aspects of communication between the motor neuron (i.e. electrical activation 
and neurotrophic) are interrupted. 
4.1. Baseline measurements - muscle atrophy and myogenin/AChE expression 
Consistent with previous studies (Chen et al. 2005; Hyatt et al. 2003; Sacheck et al. 
2007), we observed a 10% decrease in mouse gastrocnemius weight after three days of 
denervation and an approximately 40% decrease in muscle weight after fourteen days of 
denervation. In two studies of rat gastrocnemius, very similar results were obtained where 
muscle mass was reduced by 15% after three days of denervation and 55% after fourteen days 
(Sacheck et al. 2007; Hyatt et al. 2003). The degree of atrophy in rat is greater than we 
observed in mouse, but this is likely attributable to the species difference. In rat gastrocnemius 
muscle weight has been reported to be reduced by approximately 75% after roughly a month of 
denervation (Hyatt et al. 2003; Sacheck et al. 2007) but in mouse models with a similar 
denervation period, gastrocnemius muscle weight was reduced by 60% (Zhang et al. 2008). Our 
experiment did not include a denervation period of four weeks so we are unable to contrast our 
results with Zhang et al., (2008) but the above comparison between the studies of Zhang et al. 
and Hyatt et al. further corroborates a reduced severity of muscle mass loss in mouse 
gastrocnemius when compared to rat gastrocnemius. The difference in reaction between rat 
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and mouse following denervation appears fairly widespread. Physiological differences causing it 
could be as simple as a difference in fiber type composition, or more complex and linked to 
fundamental differences in gene expression patterns following denervation causing mouse 
muscle to be more “robust”, at least when comparing atrophy (see above) and protein 
expression (see below – myogenin expression). As such, we are confident in our muscle weight 
measurements and our denervation protocol, the latter of which was doubly confirmed by 
measuring myogenin/AChE expression. 
Myogenin expression was measured at the mRNA level through qPCR analysis in the 
present study. As expected, myogenin was observed to be significantly upregulated following 
denervation-induced atrophy, in line with previous studies (Buonanno et al. 1993; Adams et al. 
1995; Eftimie et al. 1991). Buoanno et al. (1993) observed a ~100 fold increase in myogenin 
expression in denervated rat hindlimb muscle after ten days while we only observed a ~13 fold 
increase in myogenin expression in mouse gastrocnemius muscle after 14 days. The same group 
observed a ~40 fold increase in myogenic expression in rat soleus muscle after 2 days of 
denervation (Eftimie et al. 1991) while at 3 days we only observed a 10 fold increase. However, 
Buanno et al. (1993) reported a 10 fold increase in myogenin expression after one day of 
denervation in rat which is exactly what we observed in mouse. A few factors may account for 
these differences at varying time points. 1) Species differences – rat muscles might respond 
differently to denervation than mouse muscle (i.e. rat muscles may be less tolerant of 
inactivation). 2) Muscle differences – we analyzed gastrocnemius muscle in our study while in 
Eftimie et al. (1991) analyzed soleus muscle and in 1993 this same group of researchers 
analyzed the following four rat hindlimb muscles: Soleus, Extensor Digitorum Longus, 
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Gastrocnemius and Tibialis Anterior, although it is unclear specifically which muscle was used to 
quantify myogenin upregulation. It has been shown that fast and slow twitch muscle fibers 
have different gene expression profiles, and hindlimb muscles contain different combinations 
of fast and slow-twitch fibers. Gastrocnemius muscle is composed mostly of fast twitch fibers, 
while soleus is predominantly comprised of slow twitch muscle fibers (Burkholder et al. 1994). 
This difference in fiber type and distribution could account for some of the variance observed. 
3) Normalization controls – The two studies discussed above used actin as a control. As seen in 
Figure 2-2 we observed large variability in actin expression at day 7. Interestingly, they 
observed a slight decrease in actin at 7 days (Eftimie et al. 1991). In the present study, we 
observed that RPS12 was a more stable normalization control, and this may account for some 
of the differences in fold change in gene expression observed in our results. 4) Experimental 
method – the above studies used northern blotting to quantify myogenin expression whereas 
we used qPCR. While both are reliable methods of mRNA quantitation, this difference in 
methodology could account for part of the variation in RNA levels observed between our study 
and other studies. qPCR is a more sensitive RNA quantitation method and can therefore detect 
more subtle differences whereas northern blotting is generally considered the standard 
method. This experimental difference cannot account for a similar difference noted in a more 
recent study which also used qPCR (MacPherson et al. 2011). MacPherson et al. showed a 30-
fold increase in myogenin expression in mice after 3 days of denervation, where we only 
observed a 10-fold increase. However, in that study, the data were normalized to actin; in 
addition it is unclear from the publication which muscles were used for mRNA analyses.  
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As an additional control measure, the expression of AChE was also measured at the 
mRNA level through qPCR analysis.  We found AChE expression to be downregulated following 
denervation induced atrophy and this is also in line with previous reports (Sketelj et al. 1998; 
Pregelj et al. 2007; Boudreau-Larivière et al. 2000). Our AChE expression data are similar to 
what has been reported in the literature. After 24 hours, a 70% reduction was reported in 
denervated mouse extensor digitorum longus (EDL) muscle (Sketelj et al. 1998) similarly, we 
observed a 61% reduction in the gastrocnemius muscle. Pregelj et al. showed an 80% reduction 
in AChE expression after 5 days in mouse EDL muscle (Pregelj et al. 2007), which is also 
comparable to our  85% reduction noted after 3 and 7 days. In rats however, the difference was 
slightly more pronounced with a 90% reduction after two days (Boudreau-Larivière et al. 2000). 
When comparing our results to those of researchers who used an identical rodent model along 
with very similar muscles (EDL and Gastrocnemius are both fast-twitch), the results obtained 
are very comparable. 
It is difficult to determine exactly why our study found a less pronounced upregulation 
in myogenin expression compared to other studies. However, a 10-fold increase in gene 
expression after 24 hours is large and in that respect, consistent with the current literature. 
Combined with our muscle atrophy data and our AChE expression data (downregulation), 
collectively these findings are consistent with what has been reported in the literature by 
various research groups to date.    
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4.2. Impact of denervation on skeletal muscle plakin expression 
The extent to which plectin, MACF and dystonin expression is affected in skeletal 
muscles that have undergone denervation-induced neuromuscular inactivation has not been 
extensively documented in the literature.  We therefore conducted a series of qPCR and 
western blot experiments to measure the mRNA and protein levels of these plakin family 
members in control versus denervated muscles. Different trends were observed for each of 
these three plakins. 
At the mRNA level, plectin was progressively downregulated over the denervation time 
course, leading to a 46% reduction in expression after seven days and a 58% reduction after 
fourteen days. However, we were unable to detect differences in plectin expression at the 
protein level at any of the denervation time points.  In comparison, dystonin showed an inverse 
pattern when comparing mRNA and protein. At the mRNA level, dystonin expression was 
gradually downregulated similar to plectin but with a 50% decrease in expression after fourteen 
days. At the protein level, dystonin protein was upregulated by approximately 50% at 7 days 
post-denervation, which tapered down to a 30% increase in expression after fourteen days.  
Finally, the change in MACF mRNA and protein was similar but slightly different in magnitude.  
In particular both mRNA and protein expression peaked after seven days of denervation but 
mRNA showed a 2.5 fold increase at day seven, while protein expression was enhanced by 67%. 
We were unable to detect significant upregulation in MACF protein expression at any other 
time point, but mRNA showed a roughly two-fold increase at days 3 and 14 without significant 
upregulation after 24 hours of denervation. 
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4.2.1. Imperfect link between mRNA and protein expression 
Although mRNA and protein expression are clearly linked with activation of DNA 
transcription and translation, the trends within each group are not necessarily obvious and/or 
co-directional. This is particularly relevant when looking at changes induced in muscle 
denervation, as the magnitude and duration of the up- or down-regulation of each may not 
coincide. 
First, following denervation, the expression of genes and their products are usually 
found to change co-directionally (i.e. both mRNA and protein upregulated, or both 
downregulated). Utrophin, for example, has been shown to be upregulated both at the mRNA 
and protein level in denervated rodent muscle (Jasmin et al. 1995). This is similar to our MACF 
expression data but in contrast to our dystonin results, where a decrease in mRNA was 
observed along with an increase in protein expression. 
Widespread changes in mRNA expression in skeletal muscle following denervation have 
been documented. Batt et al. (2006) used microarray analysis to survey the expression of 
thousands of genes. They found hundreds of examples of downregulated and upregulated 
genes following denervation lasting 30 and 90 days (Batt et al. 2006), which included MACF 
with a 3-fold upregulation in denervated muscle compared to innervated muscle. However, 
changes in dystonin and plectin were not reported which may suggest that changes in dystonin 
and plectin gene expression were not detected in the denervated muscle.  While the biological 
relevance of this data was questioned by the authors, it does provide evidence of the 
magnitude of dysregulation in denervated muscle (Batt et al. 2006), at least at the mRNA level. 
58 
 
While mRNA expression can be linked to protein expression, this is not always the case. 
Gene expression is very complex and the journey from mRNA to protein can be affected by a 
large number of post-translational processes that can affect mRNA stability (Ross 1995), or 
where translation is affected by microRNAs which can affect translational efficiency 
(Greenbaum et al. 2003; Baek et al. 2008). A study which attempted to correlate mRNA and 
protein expression during growth in yeast found a large amount of variability and claimed that 
it is not possible to deduce protein expression through mRNA expression (Gygi et al. 1999). For 
example, some mRNAs were found to be stable but lead to a 20 fold difference in protein 
expression, while the reverse was also true: stable protein expression for certain genes was the 
product of mRNA expression which could vary by up to 30 fold (Gygi et al. 1999). While Gygi 
and colleagues (1999) suggest that the correlation between mRNA and protein is usually 
positive, this correlation is very weak and there are cases of extreme variability. While the Gygi 
et al. (1999) study was attempting to establish whether protein expression could be measured 
indirectly through the much simpler method of mRNA quantification, it does show that the 
expression levels between mRNA and protein are not 1:1 and that differences in these two 
biomolecules should be expected. 
Like gene transcription and mRNA translation, protein dysregulation following 
denervation is common. For example, one study of protein expression found an upregulation of 
dystrophin and two dystrophin associated proteins, β-dystroglycan and adhalin, after two 
weeks of denervation in rat skeletal muscles using western blot analysis (Biral et al. 1996). 
Dystrophin was increased 1.5x and β-dystroglycan by 2.5x in their study, but due to the low 
abundance of adhalin in control muscle the upregulation could not be accurately measured 
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(Biral et al. 1996). We report a similar effect in our MACF results, where this plakin family 
member MACF was almost undetectable in control muscle (see Appendix B), which likely 
contributed to the difficulty in quantifying the increase in expression. 
The change in mRNA expression without a change in protein expression, as we observed 
for plectin, is therefore unsurprising. The more striking difference is dystonin upregulation at 
the protein level but a downregulation at the mRNA level. One possible explanation is that 
dystonin protein is somehow resistant to degradation (i.e. proteolysis) following denervation. 
Either through a lowered abundance of proteases which affect dystonin, or a potential 
upregulation of (speculated) proteins which could interact with dystonin to protect against 
degradation, the half-life of dystonin in denervated muscle would be in some way increased. In 
this case, it would have to be significantly increased to counteract the lowered abundance of 
mRNA transcripts.  Since dystonin mRNA levels showed a progressive decrease in expression 
while dystonin protein expression peaked at 7 days and decreased afterwards, it seems even 
the proposed transient increase in half-life of dystonin protein would not be sufficient to 
counteract progressively lowered mRNA transcript abundance. However, we did not measure 
the half-life of dystonin protein directly, and to our knowledge the half-life of dystonin has not 
been reported in the literature, therefore these arguments are speculative.  The other 
important consideration is that the 30-50% increase in dystonin protein expression post-
denervation would constitute a marginal change in protein expression and the extent to which 
this alteration has any substantial physiological relevance remains an open question.  Finally, 
MACF showed a more classic example of a positive correlation between mRNA and protein 
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expression and given that the magnitude of enhanced expression exceeds a 2-fold change, this 
could be considered more physiologically relevant.  
4.2.2. Comparison of plakins with proteins known to be dysregulated following 
denervation 
As was discussed in the Chapter 1, denervation is known to cause widespread 
dysregulation in gene expression (mRNA and protein).  For example, in rats, the levels of 
calpain-3, MHC IIB and MSE mRNA were shown to be downregulated while TRAP-2 and 
Glutamine synthetase were found to be upregulated in skeletal muscles denervated for 5 days 
(Tang et al. 2000). Proteins such as desmin, tubulin (i.e. microtubule subunit) and titin are also 
differentially regulated following denervation: desmin and tubulin are upregulated and titin is 
downregulated (Tews et al. 1997; Boudriau et al. 1996; Chen et al. 2005). A study by 
Magnusson and colleagues (2005) used high throughput microarray analysis to analyze gene 
expression in adult mouse muscle denervated for up to 6 days.  They found 116 upregulated 
genes and 89 downregulated genes with fairly strict inclusion criteria: 2x or 0.5x expression, 
respectively (Magnusson et al. 2005). Interestingly, one of the upregulated genes was in fact 
MACF whereby a 3 fold increase was reported in the supplemental information document of 
this article (Magnusson et al. 2005).   By applying similar criteria (i.e. minimum 2 fold increase 
and 0.5 fold decrease) to the present study, our plectin, dystonin and MACF mRNA expression 
data would be considered significantly different in denervated compared to innervated muscle.   
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4.2.3. Implications of the plectin, dystonin and MACF expression profile in 
denervated muscle. 
Plectin and dystonin reacted similarly to denervation compared to MACF. They were 
both downregulated at the mRNA level while MACF was upregulated at the mRNA level. At the 
protein level, however, plectin and dystonin seemed to resist downregulation with dystonin 
being slightly upregulated. This resistance to downregulation at the protein level might be 
important to preserve muscle fiber integrity following short term denervation. It has been 
shown that re-innervation after a short period of denervation (<7 days) reverses all changes in 
the muscle and longer denervation periods impair recovery, although recovery is still possible 
to some extent even after months of denervation (Finkelstein et al. 1993; Irintchev et al. 1990). 
We did not measure plakin expression beyond 2 weeks of denervation, but it is possible that 
the fairly stable dystonin and plectin protein expression after short-term denervation would 
contribute to the described recovery during re-innervation. Dystonin and plectin are large 
architectural proteins which may have partial functional redundancy (Boudreau-Larivière & 
Kothary 2002).  For instance, as described in Chapter 1, dystonin and plectin share similar 
functions such as binding to mitochondria and to the Z-line in muscle. In fact, the muscle 
isoform of dystonin binds to plectin through their mutual actin binding domains, and in plectin 
null mice dystonin is less abundant due to this association (Steiner-Champliaud et al. 2010). 
However, they are also functionally distinct in some respects. For example, the muscle-specific 
isoforms of dystonin show no binding to desmin where plectin readily binds to desmin (Steiner-
Champliaud et al. 2010). Whether or not this functional similarity and protein co-localization 
contributes to the similarities observed in dystonin and plectin expression following 
denervation remains an open question. Due to their demonstrated binding activity (Steiner-
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Champliaud et al. 2010), it could be argued that their expression at the protein level is not 
independent. One possibility is that the binding of dystonin to plectin would affect its stability 
post-denervation and this could explain their relative stability. Further research is required to 
assess if this stability is affected by the binding of plectin and dystonin, and to assess the effect 
that heightened dystonin and stable plectin protein expression has on the ability of denervated 
muscle to recover following re-innervation. 
MACF is considered to be a developmental protein in muscle tissue. MACF was found to 
be highly expressed in the nervous system, skin and skeletal muscle of embryonic day-17.5 
mice, as well as in the lung of mice right before birth (Bernier et al. 2000). However, even three 
days post-natal, MACF expression in muscle is significantly reduced while it remains strongly 
expressed in the nervous system, skin and lungs (Bernier et al. 2000). Many other genes are 
differentially regulated during development. For example, some Muscle Ring Finger proteins 
(MuRFs), specifically MuRF2, have been shown to be downregulated post-natally (Perera et al. 
2012). The 50kDa isoform of MuRF2, while highly expressed at embryonic day 15.5, is almost 
undetectable in adult muscle while the 60kDa isoform is heavily expressed shortly after birth 
but much less expressed in adult muscle (Perera et al. 2012). Other examples are nAChRs which 
exists in two isoforms, AChR-γ and AChR-ε. The gamma variant is also known as the embryonic-
type AChR; it is expressed during development but is downregulated and replaced by AChR-ε in 
adult muscle (Witzemann et al. 2013).   
 Following denervation, the expression of these genes in muscle returns to their 
developmental expression. MURFs have been shown to be upregulated following denervation 
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(Glass & Roubenoff 2010). The same happens with nAChRs, where following denervation the 
AChR-ε that are expressed in adult skeletal muscle are replaced with AChR-γ normally found in 
developing muscle (Gu & Hall 1988). During development, muscle tissue growth occurs 
independent of innervation. It is only later that nerves form synapses with the muscle fibers. 
This innervation alters the physiology of the muscle and is an integral part of muscle 
development (MacIntosh et al. 2006).  As already stated, it seems that denervation reverts 
muscle to an embryonic state, rebooting the developmental expression profile. This is 
consistent with what we observed with MACF, where denervation increases expression of a 
protein, which is not normally expressed in adult muscle, but is more highly expressed in 
developing muscle (Bernier et al. 2000).    
In the case of acetylcholine receptors, described above, the expression is transient 
similar to what we have shown for MACF. In wild-type mice, the expression of embryonic AChRs 
induced by denervation peaks roughly 5 days post-denervation. Afterwards, embryonic AChRs 
degrade and are replaced by adult AChRs, returning to innervated levels after about 20 days 
(Yampolsky et al. 2010). We did not measure MACF expression following 20 days of 
denervation, but we did observe a decrease in expression after 14 days relative to the peak 
expression at seven days. It is not known whether or not MACF would return to baseline levels 
of expression after a sufficiently long period of time.  
 Also remaining to be elucidated is determining the physiological implications of 
enhanced MACF expression in denervated muscles that are atrophying.  Does it represent a 
functional, transient adaptation in denervated muscle fibers whereby MACF offers additional 
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stabilizing support to other plakin family members (i.e. Plectin, dystonin structures)?  
Alternatively, is the enhanced MACF expression simply reflecting a shift in the gene expression 
programming towards one that recapitulates embryonic development or a combination of the 
two possibilities?  One strategy to address this point would be to generate muscle-specific 
MACF knockout mice and to study the skeletal muscle phenotype (muscle mass and gene 
expression profile) of these animals post-denervation.  It would be of interest to determine 
whether muscle atrophy would be exacerbated, minimized or comparable to control animals. 
This knockout model might also shed light on the nerve-activity induced expression of MACF. In 
normal muscle, if MACF is upregulated due to muscle reverting in some way to an embryonic 
expression profile, MACF might be powerless to affect atrophy, positively or negatively, in its 
transiently expressed state because it is not adapted to function in adult muscle. In a 
theoretical MACF knockout model, any worsening of atrophy would disprove this, implying that 
MACF upregulation may be relevant to the functioning of muscle post-denervation. 
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Chapter 5 
5. Conclusion 
We expected a downregulation in plectin and dystonin at both the protein and mRNA 
level in denervated muscle, as well as an upregulation of MACF at the protein and mRNA level.  
What we found was a downregulation of plectin and dystonin mRNA but either stable or slightly 
upregulated protein expression for plectin and dystonin respectively. For MACF the results 
were as expected, confirming previous data showing an upregulation at the mRNA level 
(Magnusson et al. 2005) but also demonstrating an upregulation at the protein level. These 
results help shed light on the gene expression profile of the skeletal muscle plakins during 
denervation-induced atrophy, providing more examples of critical structural proteins that are 
dysregulated during this type of atrophy.  
5.1.  Limitations 
This study provided some insight into expression levels of plakin proteins following 
hindlimb denervation in mice. One limitation is that the primers used for the qPCR and the 
antibodies used for the western blotting do not allow us to determine the impact of 
neuromuscular inactivation on the various individual plectin, dystonin and MACF isoforms 
predominantly expressed in skeletal muscle.  Our mRNA and protein expression data are rather 
an overall expression profile of each plakin family member. Furthermore, the results have to be 
taken in the context of the fairly small sample size of mice (n=8) used. While in line with many 
other rodent studies, the small number of animals used reduces the statistical power, especially 
when considering the high variance western blot data. High molecular weight western blotting 
is a standard method for assessing protein expression, and while large changes can be observed 
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in the data, other more subtle trends can be missed.  Finally, our data do not allow us to 
determine the exact underlying molecular mechanisms that lead to the changes in mRNA and 
protein expression of the target plakins (i.e. transcriptional vs post-transcriptional 
mechanisms). 
5.2. Future Directions 
Further studies on plakin protein expression in denervated muscle could involve the 
development of mice with a conditional MACF knockout in muscle (as MACF knockouts are 
embryonic lethal). This knockout could be used to assess the roles of MACF in postnatal 
development, if any exist. Specifically relating to denervation, a conditional MACF knockout in 
muscle would allow us to evaluate the role of MACF following denervation. Its marked 
upregulation, while likely a direct result of the lack of neural activity, could have no regulatory 
or structural role, or perhaps MACF upregulation does serve some role in denervated muscle 
and the upregulation following denervation is beneficial. 
Short of developing a conditional MACF knockout mouse, further studies on plakin 
expression following denervation that are isoform-specific could shed light on the denervation-
related regulatory and structural role of various isoforms. For example, what isoforms of plectin 
that are expressed in muscle are affected more or less during denervation. Perhaps plectin 1d 
and 1f are upregulated while plectin 1b, which affect mitochondrial stability, are less important 
when neural activity is inhibited. In this case some plectin variants would be upregulated while 
some are downregulated, leading to our observed stable expression. It is also possible that all 
isoforms of plectin (and other muscle plakins within the same family) are affected similarly 
following denervation. Only isoform specific studies could determine this. 
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Future studies could also be conducted to determine the impact of skeletal muscle 
hypertrophy on the expression profile of plectin, dystonin, and MACF isoforms by using a 
surgical intervention such as tenotomy of hindlimb muscle whereby all tendons except that of 
one muscle, typically that of the plantaris, is left intact thereby leaving the plantaris to take on 
the entire load of foot flexion.   It would be interesting to see if enhanced neuromuscular 
activity leading to muscle hypertrophy would impact plakin expression.  
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Appendices 
 
Appendix A: RNA integrity of all samples 
 
RNA integrity gels.  Aliquots of each sample pair (denervated and sham; total of 45 samples 
subsequently processed for qPCR) were resolved on ethidium bromide stained agarose gels.  
For each animal ID (100 to 145), the first lane corresponds to the denervated (den) limb sample 
and the second lane corresponds to the contralateral control (sham). Clear 28S and 18S 
ribosomal RNA bands indicate samples that are free of RNA degradation. Two of the samples, 
131-sham and 136-sham were not visible in their first run and are indicated by the long arrows. 
To determine if this was a loading error or some other type of experimental error, these two 
samples were resolved on a second gel. After the second run, 131-sham was detected but 136-
sham sample was not.  RNA was also undetectable for sample 136-sham after performing the 
spectrophotometric analysis. Animal 136 was therefore excluded from the qPCR analyses.  
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Appendix B: Comprehensive set of all western blot images 
 
See methodology section for information on immunoblotting experiments. From left to right: 
plectin, dystonin and MACF blots and top to bottom: days 1, 3, 7 and 14. Numbers to the right 
of each blot correspond to the blot number (see Appendix C for corresponding coomassie-
stained membranes). Lines to the left of the blots correspond to the 460kDa band of the 
HiMark protein ladder.  
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Appendix C: Coomassie stained membranes used for normalization 
 
In total 13 membranes were used for the final analysis. At first immunoblotting experiments 
were attempted with 50ug of protein but the signal was very weak. We then used 100ug and 
determined that signal detection was significantly improved. The lines to the left of each gel 
represent molecular weight bands which, from top to bottom, correspond to 460, 268, 238 and 
171kDa bands. 
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Appendix D: Animal Use Protocol certificate 
 
 
TO:  Céline Boudreau-Larivière 
 
FROM: David MacLean  
 
DATE: March 14, 2013 
 
RE: AUP: 2013-03-02: Plakin expression in denervated mouse hind limb 
skeletal muscle 
 
 
Dr. Boudreau-Larivière, 
 
On March 13, 2013, the Animal Care Committee met to consider the above-
mentioned AUP and voted to approve it. 
 
Please provide a signed copy of the revised AUP to Pauline Zanetti (Research, 
Development and Creativity Office). 
 
 
 
Sincerely, 
 
 
 
David MacLean, Ph.D. 
Chair of the Animal Care Committee 
 
